GlassScriptPhysician profile
Lisa M Hills
NPI 1003289562
$3,600.26
in general payments reported to CMS, 2019-2025
28 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,133 · 2022: $757 · 2023: $659 · 2024: $596 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $502.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $461.54 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.67 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $252.43 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $164.72 | 2021-2025 | |
| Amarin Pharma, INC. | $132.59 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.75 | 2021-2023 | Xifaxan |
| Esperion Therapeutics, INC. | $100.31 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.85 | 2022-2023 | Eliquis, Camzyos |
| Amgen INC. | $91.14 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $75.70 | 2021-2024 | Capvaxive |
| Astellas Pharma US INC | $74.03 | 2021-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $61.85 | 2021 | |
| Dexcom, INC. | $46.22 | 2024-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.13 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $42.95 | 2023-2024 | Watchman Flx, Watchman Access System |
| Radius Health, INC. | $34.09 | 2025 | Tymlos |
| Lilly USA, LLC | $28.41 | 2021-2024 | Zepbound |
| Nevro Corp. | $22.43 | 2022 | |
| Sanofi Pasteur INC. | $19.84 | 2023 | |
| Abbott Laboratories | $19.74 | 2022 | |
| Harmony Biosciences LLC | $16.13 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.86 | 2023 | Keveyis |
| Verona Pharma, INC. | $14.86 | 2025 | Ohtuvayre |
| Nestle Healthcare Nutrition INC. | $14.56 | 2021 | |
| Cequr Corporation | $10.00 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.